Stubborn cancer tumors were completely (and safely) eliminated in a mouse model with a small but mighty treatment method using nanoparticles, ...

Good morning. My name is David, and I'll be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] I'd like to introduce Beth DelGiacco, Vice President ...

In a mouse model, a new approach has led to the formation of new neural connections in the injured spinal cord, partially restoring lost function. However, further steps and studies are needed before ...

The biology behind muscle pain: calcium chaos, microscopic damage, and the overlooked mechanism that explains how statins can ...

Net sales increased to $31.5 millionGross margin improved to 63.5%Net income of $6.3 million, up $1.3 million from the prior ...

The last time I wrote about BioMarin Pharmaceutical (BMRN) it was with a Seeking Alpha article entitled "BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401." With respect to this ...

Medical Scientist Training Program, The University of Pennsylvania Perelman School of Medicine, Philadelphia, United States ...

Norton’s previous rebirth ended badly. The new TVS-backed era begins properly with the Manx R, a 1200 cc V4 superbike ...

Jeffrey Stansbury, Ph.D., senior associate dean for research and professor at the CU Anschutz School of Dental Medicine, has ...

Three forces shape every business’s AI strategy: geography and AI’s geopolitical context; the increasing complexities of the AI value chain; and ...

Johnson & Johnson today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, TREMFYA ...

Developing AI capabilities is a strategic focus for every company, with acquisitions one of the primary ways businesses can rapidly move up ...